Pharvaris N V.
infoPharvaris N.V. is a small cap stock with a total market cap of 816.46M.
infoThey trade on the NASDAQ and had their IPO 2 years and 6 months ago.
infoPharvaris N.V. currently employs 68 people.
infoAs of Wednesday, Aug 23 2023, Pharvaris N.V.’s share price is $20.0.
News Relating to Pharvaris N.V.
GlobeNewsWire
Pharvaris To Present at the 2023 HAEi Regional Conference EMEA
Wednesday Aug 23 2023 at 06:50
ZUG, Switzerland, Aug. 23, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of three abstracts for presentation at the HAEi Regional Conference EMEA, taking place in Munich from September 1-3, 2023.
Seeking Alpha
Pharvaris: FDA Lifts Clinical Hold, Progresses HAE Drug Development
Thursday Jul 27 2023 at 03:31
Pharvaris, a clinical-stage company, has reported a cash position of €135 million as of March 31, 2023, indicating an operational runway of approximately 18 months at current loss rates. The company’s product pipeline, including PHVS416 and PHVS719, targets bradykinin-mediated diseases like HAE, with the FDA recently lifting a clinical hold on the IND application for deucrictibant. Despite promising developments, Pharvaris faces risks including potential off-target effects, unforeseen safety issues or insufficient efficacy in clinical trials, and regulatory hurdles.
The Motley Fool
Why Shares of Pharvaris N.V. Are Up Tuesday
Tuesday Jun 27 2023 at 12:11
Pharvaris has only one drug, deucrictibant, in its pipeline. Deucrictibant is being examined to treat hereditary angioedema (HAE), which can cause painful swelling.
GlobeNewsWire
Pharvaris to Present in Upcoming March Investor Conferences
Thursday Mar 02 2023 at 06:50
ZUG, Switzerland, March 02, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will participate in two upcoming investor conferences in March:
GlobeNewsWire
Pharvaris to Present at SVB Securities Global Biopharma Conference
Wednesday Feb 08 2023 at 06:50
ZUG, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will present at the SVB Securities Global Biopharma Conference taking place virtually from February 14–16, 2023.
Seeking Alpha
Pharvaris: Focused Pipeline On Hereditary Angioedema
Friday Jan 13 2023 at 08:00
Pharvaris has a pipeline fully focused on HAE. Their molecule has a differentiated value proposition.
Proactive Investors
Pharvaris shares soar on positive top-line Phase 2 data from RAPIDe-1 study as it releases 3Q results
Thursday Dec 08 2022 at 11:34
Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, has announced positive top-line data from its RAPIDe-1 Phase 2 clinical study, sending its shares soaring in early trade. Releasing the results alongside its third-quarter financials, the Zug, Switzerland-based company said the data demonstrates statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks.
InvestorPlace
Why Is Pharvaris (PHVS) Stock Up 62% Today?
Thursday Dec 08 2022 at 10:37
Pharvaris (NASDAQ: PHVS ) stock is heading higher on Thursday following the release of positive results from a Phase 2 clinical study. That clinical trial covers PHVS416, which is an oral treatment for hereditary angioedema ( HAE ) attacks.
Investors Business Daily
Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn’t Worried
Monday Aug 22 2022 at 12:18
Biotech stock Pharvaris plummeted Monday after the Food and Drug Administration placed a pair of its clinical studies on hold. The post Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn’t Worried appeared first on Investor’s Business Daily.
GlobeNewsWire
Pharvaris to Participate in Upcoming April Investor Conferences
Wednesday Apr 06 2022 at 16:10
ZUG, Switzerland, April 06, 2022 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced that management will participate in two upcoming investor conferences in April:
GlobeNewsWire
Pharvaris to Participate in 11th Annual SVB Leerink Global Healthcare Conference
Wednesday Feb 09 2022 at 08:10
ZUG, Switzerland, Feb. 09, 2022 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually from February 14–18, 2022.
GlobeNewsWire
Pharvaris to Participate in Upcoming September Investor Conferences
Friday Sep 03 2021 at 08:00
ZUG, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that management will participate in the following three upcoming investor conferences in September:
GlobeNewsWire
Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights
Friday Jul 30 2021 at 08:00
ZUG, Switzerland, July 30, 2021 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today reported financial results for the second quarter ended June 30, 2021, and provided an update on recent business highlights.
Pulse2
PHVS Stock Increases Over 13% Pre-Market: Why It Happened
Monday Jul 12 2021 at 08:22
The stock price of Pharvaris NV (NASDAQ: PHVS) increased by over 13% pre-market. This is why it happened.
GlobeNewsWire
Pharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021
Friday Jul 09 2021 at 18:10
Multiple doses of PHA121 were well-tolerated and showed a favorable pharmacokinetic profile for prophylactic treatment of HAE Multiple doses of PHA121 were well-tolerated and showed a favorable pharmacokinetic profile for prophylactic treatment of HAE
GlobeNewsWire
Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021
Thursday Jul 01 2021 at 07:00
ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that the company will present clinical data for oral PHA121, a novel and potent bradykinin 2 receptor antagonist for treatment of hereditary angioedema, as an e-Poster at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021, to be held virtually July 10-16, 2021.
GlobeNewsWire
Pharvaris Announces Annual Meeting of Shareholders
Friday Jun 11 2021 at 08:00
ZUG, Switzerland, June 11, 2021 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the annual general meeting of shareholders will take place on Tuesday, June 29, 2021 at 1:00 p.m. CEST (7:00 a.m. EDT).
GlobeNewsWire
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE, at 12th C1 Inhibitor Deficiency and Angioedema Workshop
Friday Jun 04 2021 at 03:45
ZUG, Switzerland, June 04, 2021 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that Anne Lesage, Ph.D., chief early development officer at Pharvaris, will present bradykinin challenge data supporting the pharmacokinetic (PK) and pharmacodynamic (PD) profile of PHA121 (PHA-022121) for the treatment of hereditary angioedema (HAE), at the 12th C1 Inhibitor Deficiency and Angioedema Workshop, to be held virtually June 3-6, 2021.
GlobeNewsWire
Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights
Thursday Apr 29 2021 at 16:15
ZUG, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today reported financial results for the year ended December 31, 2020, and provided recent business highlights.
GlobeNewsWire
Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE
Friday Feb 26 2021 at 08:00
ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced dosing of the first patient in RAPIDe-1, an on-demand Phase 2 study evaluating the efficacy, safety, and pharmacokinetics of PHVS416 in patients with HAE due to C1-Inhibitor Deficiency type 1 and 2.
GlobeNewsWire
Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting
Friday Feb 19 2021 at 10:00
Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers Single-dose treatment of PHA121 demonstrated effective bradykinin inhibition in healthy volunteers
Seeking Alpha
U.S. IPO Weekly Recap: Biotechs Flood The IPO Market In A 14 IPO Week
Monday Feb 08 2021 at 02:14
The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. German chemicals group Atotech downsized and priced below the range to raise $498 million at a $3.3 billion market cap.
Barrons
The Biotech IPO Wave Continues. Here Are 7 Stocks Hitting the Market.
Friday Feb 05 2021 at 13:28
A flock of biotech companies are opening for trading Friday. Most of the deals grew in size, with price increases as well.
Pharvaris N.V. Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Pharvaris N.V.’s Altman Z-score is 26.52 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
Pharvaris N.V. Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Pharvaris N.V..
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Pharvaris N.V.’s Income Quality of 1.17 is greater than its Industry Group of 0.69 (69.6% greater)
Pharvaris N.V.’s Income Quality of 1.17 is greater than its Major Industry Group of 0.71 (64.8% greater)
Pharvaris N.V.’s Income Quality of 1.17 is greater than its Sector of 0.75 (56.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Pharvaris N.V.’s Current Ratio of 11.89 is greater than its Industry Group of 4.76 (149.8% greater)
Pharvaris N.V.’s Current Ratio of 11.89 is greater than its Major Industry Group of 4.32 (175.2% greater)
Pharvaris N.V.’s Current Ratio of 11.89 is greater than its Sector of 2.6 (357.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-10.8 & -1.27)
Cannot compare a negative PE Ratio (-10.8 & -1.1)
Cannot compare a negative PE Ratio (-10.8 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Pharvaris N.V.’s PB Ratio of 4.33 is greater than its Industry Group of 1.34 (223.1% greater)
Pharvaris N.V.’s PB Ratio of 4.33 is greater than its Major Industry Group of 1.4 (209.3% greater)
Pharvaris N.V.’s PB Ratio of 4.33 is greater than its Sector of 1.62 (167.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Pharvaris N.V.’s ROE of -0.4 is in line with its Industry Group of -0.44 (9.1% greater)
Pharvaris N.V.’s ROE of -0.4 is in line with its Major Industry Group of -0.38 (-5.3% lower)
Pharvaris N.V.’s ROE of -0.4 is lower than its Sector of -0.03 (-1233.3% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Pharvaris N.V.’s ROCE of -0.38 is in line with its Industry Group of -0.42 (9.5% greater)
Pharvaris N.V.’s ROCE of -0.38 is in line with its Major Industry Group of -0.37 (-2.7% lower)
Pharvaris N.V.’s ROCE of -0.38 is lower than its Sector of -0.04 (-850.0% lower)
Derived from SEC.GOV filing dataopen_in_new